BioSpace

Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset

After a series of clinical-stage failures, Alector is resetting around its preclinical blood-brain barrier delivery technology, securing a big pharma partnership along the way.

By BioSpace

1 min read
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset
Genentech pens $1.27B deal to access Alector’s preclinical blood-brain barrier asset

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights